Curevo Vaccine

We're very excited to announce positive updated Phase 2 data from our 876-participant head-to-head trial of amezosvatein versus Shingrix. At one year post the second dose of each vaccine, anti-gE antibody immunogenicity for the 100 μg gE antigen plus 15 μg SLA-SE dose of amezosvatein remained non-inferior to Shingrix. Additional safety, reactogenicity, and shingles case outcomes data are summarized in our press release.

Curevo Vaccine to Present at the 43rd Annual JP Morgan Healthcare Conference Seattle, WA – January 8, 2025 – Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced it has been selected to present in the Private Company Track at the 43rd Annual J.P. Morgan Healthcare Conference. Curevo’s CEO, George Simeon, will discuss updated data from Curevo’s 876-patient head‑to‑head trial of amezosvatein, a non-mRNA adjuvanted subunit vaccine for shingles, versus Shingrix®. The presentation will occur on Wednesday, January 15th at 5:00 pm Pacific Standard USA Time in the Golden Gate room (32nd floor). https://lnkd.in/gafZhS7Z

Curevo Presents Positive Shingles Vaccine Outcomes Data -- Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine -- Ten shingles cases would have been expected absent vaccination -- Updated data will be featured in an oral presentation at the World Vaccine Congress Barcelona, 31 October 2024, in Theatre 5 at 13:30 CEST  https://lnkd.in/ggRQbvTZ

We are presenting data on our Phase 2 trial of amezosvatein versus Shingrix for the prevention of herpes zoster at IDWeek 2024 underway in Los Angeles. It is poster # 597, available October 17th (tomorrow) from 12:15 to 1:30pm PDT in Hall J & K. We issued a press release about the data this morning. https://lnkd.in/eGvkqsqa Dr. William Smith, the primary investigator on the Phase 2 trial, had this to say about the data: "Shingles is a very serious disease with effects often outlasting the painful rash. If these amezosvatein data are confirmed in Phase 3 trials and the vaccine is approved, I expect its lower reactogenicity rates will help get more people protected against shingles.”

We are #hiring.  The CMC Operations Team at Curevo Vaccine is looking to hire a Sr. CMC Manager, CMC Operations.  Your role will involve driving the CMC programs at CDMOs for development, scale-up, cGMP manufacturing, process characterization, and qualification for phase III clinical studies and commercial supply. If you are passionate about vaccine development, Curevo Vaccine is the place for you. Reach out to me directly, Sabreena.Tressler@tsptalent.com or apply using the link – https://lnkd.in/e-YTzTbH #adjuvantvaccines #vaccinedevelopment #infectiousdisease #processdevelopment #latephasedrugdevelopment #biologics #drugproductprocessvalidation #proteinproduction #proteinpurification #formulationdevelopment #lyophilizedrecombinantprotein

Curevo will be attending two global investor healthcare conferences in June. We'll be attending the Jefferies Global Healthcare Conference June 4-6 in New York. 1:1 slots are available and we're also available to meet outside the conference for those in the NYC area. June 10-13, we're presenting at the Goldman Sachs' 45th Annual Global Healthcare Conference in Miami. 1:1s are available for those attending the conference.

Curevo will be attending two global investor healthcare conferences in June. We'll be attending the Jefferies Global Healthcare Conference June 4-6 in New York. 1:1 slots are available and we're also available to meet outside the conference for those in the NYC area. June 10-13, we're presenting at the Goldman Sachs' 45th Annual Global Healthcare Conference in Miami. 1:1s are available for those attending the conference.

Curevo’s CEO, George Simeon, will be presenting at the Citizens JMP Life Science Conference in NYC on May 14 at noon in Room B of the conference. George and David Miller, Curevo’s Sr. Dir. Of Strategic Communications, will be available Monday and Tuesday for 1:1s with investors at the conference or in the NYC area.